![]() |
First results from whole-genome sequencing clinical trial on triple negative breast c
Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin-(trastuzumab).
More... |
| All times are GMT -7. The time now is 11:46 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2025, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021